Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

PR Newswire February 4, 2022

RVNC 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Feb. 8th Deadline in Securities Fraud Suit

Newsfile February 4, 2022

Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 4, 2022

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)

Business Wire February 4, 2022

DEADLINE NEXT WEEK: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC

Newsfile February 3, 2022

Revance Therapeutics Shareholder Notice

Newsfile February 3, 2022

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC

Newsfile February 3, 2022

RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire February 3, 2022

Deadline Tuesday Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 3, 2022

RVNC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022

Newsfile February 3, 2022

Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Revance Therapeutics, Inc. (RVNC) Investors

Newsfile February 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

Newsfile February 2, 2022

Revance Therapeutics Shareholder Alert

Newsfile February 2, 2022

RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire February 2, 2022

Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 2, 2022

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.

Newsfile February 1, 2022

Revance Therapeutics Deadline Alert

Newsfile February 1, 2022

RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders

PR Newswire February 1, 2022

RVNC Alert: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class Action

Newsfile February 1, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Revance Investors of a Lead Plaintiff Deadline of February 8, 2022

PR Newswire January 31, 2022